SCHEMBL4666463

SCHEMBL4666463

Cc1c(-c2ccc(N3C(=O)C=CC3=O)cc2)c(=O)oc2ccccc12

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EP300 Q09472 1/20 0.63
ERAP1 Q9NZ08 1/20 0.48
MGLL Q99685 4/20 0.47
FAAH O00519 2/20 0.47
MAOB P27338 1/20 0.44
KDM4E B2RXH2 3/20 0.43
NPC1 O15118 2/20 0.41
ALDH1A1 P00352 2/20 0.40
STAT1 P42224 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
CA9 Q16790 3/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
TSHR P16473 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HIF1A Q16665 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29473710 1.00 EP300 (0.63) EP300ERAP1MGLLFAAHMAOB
SCHEMBL4449250 0.81 ERAP1 (0.68) ERAP1MAOBKDM4ENPC1ALDH1A1
SCHEMBL7750137 0.80 EP300 (0.78) EP300ERAP1MGLLKDM4ENPC1
SCHEMBL7121658 0.79 CA1 (0.56) ERAP1MAOBKDM4ENPC1ALDH1A1
SCHEMBL29412863 0.78 EP300 (1.00) EP300ERAP1KDM4ENPC1ALDH1A1
SCHEMBL38666492 0.78 EP300 (0.67) EP300ERAP1MGLLMAOBKDM4E
SCHEMBL6627 0.78 EP300 (1.00) EP300ERAP1KDM4ENPC1ALDH1A1
SCHEMBL28832501 0.77 EP300 (0.53) EP300ERAP1MGLLFAAHKDM4E
SCHEMBL28131701 0.77 KDM4E (0.50) MGLLKDM4EALDH1A1KMT2ACA9
SCHEMBL7117054 0.76 MAOB (0.72) ERAP1MAOBKDM4ENPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3172211-A1 COMPOUNDS GlaxoSmithKline Intellectual Property Development Limited (GB) 2017-05-31 EP disclosed
EP-3172208-A1 COMPOUNDS GlaxoSmithKline Intellectual Property Development Limited (GB) 2017-05-31 EP disclosed
WO-2016011931-A1 COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2016-01-28 WO disclosed
WO-2016011930-A1 COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2016-01-28 WO disclosed
EP-0919565-B2 Labeled oligonucleotides HOFFMANN LA ROCHE (CH) 2008-11-12 EP disclosed
US-7445900-B2 Homogeneous assay system ROCHE MOLECULAR SYSTEMS, INC. (US) 2008-11-04 US disclosed
US-20080171315-A1 Homogeneous assay system GELFAND DAVID H 2008-07-17 US disclosed
EP-1302549-B1 Process for discriminating sequence variants HOFFMANN LA ROCHE (CH) 2007-06-27 EP disclosed
US-7141377-B2 Process for discrimination of nucleic acid sequence variants ROCHE MOLECULAR SYSTEMS, INC. (US) 2006-11-28 US disclosed
US-20060257885-A1 Homogeneous assay system GELFAND DAVID H 2006-11-16 US disclosed
US-20060078914-A1 Homogeneous assay system GELFAND DAVID H 2006-04-13 US disclosed
US-20050255499-A1 Process for discrimination of nucleic acid sequence variants ROCHE MOLECULAR SYSTEMS, INC. 2005-11-17 US disclosed
EP-0919565-B1 Labeled oligonucleotides HOFFMANN LA ROCHE (CH) 2003-10-15 EP disclosed
EP-1302549-A2 Process for discriminating sequence variants F. HOFFMANN-LA ROCHE AG (CH) 2003-04-16 EP disclosed
US-6214979-B1 Homogeneous assay system ROCHE MOLECULAR SYSTEMS 2001-04-10 US disclosed
EP-0543942-B1 HOMOGENEOUS ASSAY SYSTEM HOFFMANN LA ROCHE (CH) 2001-01-24 EP disclosed
EP-0919565-A2 Labeled oligonucleotides F. HOFFMANN-LA ROCHE AG (CH) 1999-06-02 EP disclosed
US-5804375-A PAIR OF NUCLEOTIDE PRIMERS AND LABELED OLIGONUCLEOTIDE ROCHE MOLECULAR SYSTEMS, INC. (US) 1998-09-08 US disclosed
EP-0543942-A1 HOMOGENEOUS ASSAY SYSTEM F. HOFFMANN-LA ROCHE AG (CH) 1993-06-02 EP disclosed
WO-1992002638-A1 HOMOGENEOUS ASSAY SYSTEM F. HOFFMANN-LA ROCHE AG (CH) 1992-02-20 WO disclosed